Zymogenetics, Inc.

Blaze Bioscience, Inc.

Bristol-myers Squibb Compnay

Julia E Novak

Scott R Presnell

Angela K Hammond

Cindy A Sprecher

Jane A Gross

Stacey R Dillon

Richard D Holly

Andrew J Nelson

Donald C Foster

Janet V Johnston

Darrell C Conklin

Francis J Grant

James William West

Natalie Winblade Nairn

Dennis M Miller

Wenfeng Xu

Hal Blumberg

Claudia Jochheim

Stacey J Hansen

Stephen R Jaspers

Paul O Sheppard

Wayne R Kindsvogel

Zeren Gao

Kevin M Klucher

Joseph Leon Kuijper

Maria M Dasovich

Theodore E Whitmore

Yasmin A Chandrasekher

Mark R Stroud

Penny Thompson

Valorie R Wiss

Kelly Byrnes-Blake

James D Kelly

Yue Yao

Emma E Moore

Catherine E Lofton-Day

Randal Henne

Fenella C Raymond

Karen L Madden

Greg T Hermanson

Kenneth Grabstein

Maribeth A Eagan

Xu Wenfeng

Maribeth A Eagen

Compositions and formulations comprising chlorotoxin conjugate compounds are provided, including native and modified variants of chlorotoxin peptide conjugated to detectable agents or active agents. Methods of detecting and treating ductal carcinoma in situ breast cancer, invasive ductal carcinoma breast cancer, lobular carcinoma in situ, invasive lobular carcinoma, and triple-negative breast cancer with chlorotoxin conjugate compounds are also provided, including methods of imaging tumor tissues and cells.

Methods of treating breast cancer

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

Tissue-homing peptide conjugates and methods of use thereof

Peptide-immuno-oncology agent complexes ('peptide-I/O complexes') that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.

Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptide-active agent conjugates are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the kidney. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

Renal-homing peptide conjugates and methods of use thereof

Cartilage-homing peptide conjugates and methods of use thereof

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

Methods of producing a zcytor17 heterodimeric cytokine receptor

ZCYTOR17 heterodimeric cytokine receptor

A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

Method of treating rheumatoid arthritis using anti-IL-20 antibodies

ZCYTOR17 heterodimeric cytokine receptor polynucleotides

Methods of treatment using anti-IL-20 antibodies

Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.

Cytokine zalpha11 ligand

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Methods for producing cytokine receptor ZALPHA11

Cytokine zalpha11 ligand antibodies

Growing community of inventors

Bainbridge Island, WA, United States of America

Julia E Novak